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Cholesterol levels and cholesterol
lowering in idiopathic dilated
cardiomyopathy
We read with great interest the recent article
of Dr Christ et al.1 about the prognostic
signiﬁcance of serum cholesterol levels in
patients with idiopathic dilated cardio-
myopathy (IDC). It was found that decreased
cholesterol levels do not independently
predict adverse prognosis in patients with
IDC and that low cholesterol levels are depen-
dent on the severity of the disease (i.e.
higher NYHA class, higher left ventricular
end-diastolic diameter, and lower left ventri-
cular ejection fraction). In contrast, the
authors present an intriguing curve showing
that, retrospectively, the prognosis (survival
or transplant free survival) was signiﬁcantly
better for the few patients (15%) who
received statins at any time during follow-
up. As stated in the discussion, beneﬁcial
effects of statins in heart failure patients
indeed appear promising in some preliminary
results, even in patients without coronary
artery disease.2 However, the particular
analysis and results of Dr Christ may, in our
opinion, be related to the fact that the
patients who received statins were likely to
be those with the highest cholesterol levels,
i.e. those with the lower severity of the
disease as suggested by the authors them-
selves. Therefore, it is really not sure that
the better prognosis was related to the treat-
ment with statins or to the lipid lowering.
Prospective randomized intervention trials
are thus particularly needed in the ﬁeld.
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Cholesterol levels and cholesterol
lowering in idiopathic dilated
cardiomyopathy: reply
We greatly appreciate the comments of
Fauchier et al. regarding our recently
published ﬁndings.1 Experimental and
observational studies have raised concerns
whether cholesterol lowering may adversely
affect outcome in patients with chronic
heart failure. We believe that those studies
may not adequately address this clinically
important issue due to (i) the artiﬁcial
nature of those experimental studies and
(ii) the mixed patient populations analysed
including patients with coronary artery
disease, which is an inﬂammatory disease by
itself.
Owing to the exceptional opportunity in
our institution, where patients with idio-
pathic dilated cardiomyopathy (iDCM) have
been followed for several years (Marburg
cardiomyopathy database), we have been
able to examine aforementioned questions
in a large cohort of iDCM patients, in whom
systolic dysfunction due to other causes has
been included on thorough examinations.
Our data of this well-characterized patient
group convincingly demonstrate that chole-
sterol levels depend on the severity of
cardiac disease. Surprisingly, further analysis
indicates that statins may beneﬁcially affect
outcome in iDCM patients supporting
experimental and preliminary clinical
ﬁndings in this ﬁeld.2,3 Although our data
appear conclusive, they were derived from
post hoc analysis with all limitations
inherent with subgroup analysis. In addition,
(i) a large number of patients on statins did
not receive those drugs throughout the
whole observational period; (ii) it cannot
be excluded that iDCM patients with high
cholesterol levels, which is associated with
better outcome as already demonstrated in
our study, are preferentially treated with
statins leading to bias, although we have
tried to adjust during statistical analysis.
Subsequently, our data need to be conﬁrmed
by well-designed, prospective, randomized
trials as suggested by Fauchier. Randomized
clinical studies are already on the way to
clarify this exciting concept (http://cvm.
controlled-trials.com/content/2/6/266).
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Combined pharmacologic treatment
with clopidogrel and statin for
patients with acute coronary
syndrome: is there a survival
advantage?
We read with great interest the retrospec-
tive study by Lim et al.1 on the impact of
combined treatment of anti-platelet drugs
and statin on the clinical outcomes of
patients with acute coronary syndrome
(ACS). The authors in their study suggest
that despite the possibility of competitive
drug interaction between statin and clopido-
grel,2 the combination of clopidogrel and
statin has beneﬁcial synergetic effects on
the mortality of patients with non-ST-
segment elevation ACS.
Randomized controlled trials over the past
20 years clearly show that aspirin, beta-
blocker, ACE-inhibitor, and statin therapies
prevent recurrent coronary events in
patients with ACS.3,4 In particular, statins
have been associated with a substantial
reduction of vascular morbidity and
mortality. The beneﬁts of statin therapy
have been demonstrated in patients with
coronary artery disease, hypertension,
diabetes, and in those with elevated,
averaged,5 or even near-normal LDL-
cholesterol levels.6 Statins are known to
promote an overall 24–37% reduction in
the relative risk for coronary events,
independent of other confounding variables
such as age and sex (for review refer to
Gotto7). Thus, statins are recommended in
the current therapeutic guidelines for the
treatment of ACS.3,4
Data provided by Lim et al.1 show that the
6-month mortality estimated by the Kaplan–
Meier curve was signiﬁcantly lower in group
IV (aspirinþ clopidogrelþ statin) compared
with group II (aspirinþ clopidogrel). We
would like to make the following important
notes: (1) the beneﬁts of statins, beta-
blockers, and ACE-inhibitors on the
morbidity and mortality of patients with
ACS have been well documented, (2) a
statistically signiﬁcant greater number of
group IV patients compared with group II
were on beta-blockers and ACE-inhibitors in
the study conducted by Lim et al.,1 and (3)
ex vivo studies of clopidogrel and statin
drug interactions show signiﬁcant inhibition
of clopidogrel metabolism but not statin
efﬁcacy.
Therefore, this suggests that the low
mortality observed by Lim et al.1 within
group IV compared with group II could be
simply attributed to the independent statin
effect and/or to the effect of beta-blockers
and ACE-inhibitors. The Lim et al.1 study
shows that statin signiﬁcantly reduces the
mortality in the ‘treated’ group IV compared
with the ‘non-treated’ group II, and
aspirinþ clopidogrel could be considered as
a background for both groups. In addition,
the mortality rate of group III (aspirinþ
statin) and group II (aspirinþ clopidogrel)
were 3.6 and 4.4%, respectively. This
further indicates the value of statin
therapy in patients with ACS.
The Kaplan–Meier curve in the Lim et al.1
study shows only the unadjusted mortality
for group II vs. group IV. ‘Restricting the
main study comparisons to the two groups
in whom clopidogrel was used’, as stated
by the authors, might not be sufﬁcient to
evaluate the synergistic effect of the drugs
of interest on overall mortality. To
investigate the additive and/or synergetic
effect of clopidogrel and statin, Kaplan–
Meier plot should include the adjusted
mortality of all the four groups studied by
Lim et al.
In conclusion, the retrospective study
conducted by Lim et al.1 in ACS patients
makes it difﬁcult to draw the conclusion
that a ‘clinically’ superior effect exists for
clopidogrel–statin drug combination. More-
over, the conclusion of additive or synergetic
effects of the combined two drugs on the
clinical outcomes of patients with ACS
warrants further investigation.
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